CVTX - CV Therapeutics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Todd N. Weisrock who started this subject	10/6/2003 9:11:56 PM
From: mopgcw	of 411

UPDATE - CV Therapeutics files $252.5 mln mixed shelf Friday October 3, 6:47 am ET WASHINGTON, Oct 3 (Reuters) - CV Therapeutics Inc. (NasdaqNM:CVTX - News) on Friday filed with the Securities and Exchange Commission (News - Websites) to periodically sell up to $252.5 million in debt securities, preferred and common stock, and warrants. ADVERTISEMENT The Palo Alto, California-based biotechnology company said it plans to use the proceeds from the shelf offering for general corporate purposes, which may include research and development, product manufacturing, clinical trials and filing of new drug applications. CV shares closed at $22.05 Thursday on the New York Stock Exchange (News - Websites). They have ranged from $15.73 to $41.50 in last 52 weeks. The shelf registration statement includes another $47.5 million in previously registered but unissued securities for a total of $300 million. Under a shelf registration, a company may sell securities in one or more separate offerings with the size, price and terms to be determined at the time of sale.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next